Pay in 4 interest-free payments of $5.72 Learn more
Ships within 48 hours · Estimated delivery Oct 29 - Nov 3
When AOD-9604 binds to or modulates these receptors, it preferentially activates fat cells while having minimal effects on other tissues that primarily express beta-1 and beta-2 adrenergic receptor subtypes
5-Amino-1MQ injection should be administered subcutaneously (under the skin) using a 29-31 gauge insulin syringe
If travel involves heat, cold, or long delays, ask the dispensing pharmacist how to keep the product within the labeled storage range
Can GLOW be used for injuries
04 Injection-site reaction Mild redness or swelling at the injection site is the most commonly reported AOD-9604 adverse event in trials
The molecular target that AOD-9604 actually binds is still unidentified, which the FDA explicitly noted in its December 2024 evaluation
US$ 23.38
US$ 27.56
US$ 28.01
US$ 23.63
US$ 29.87
US$ 29.06
